MOTS-c, or Mitochondrial Open Reading Frame of the 12S rRNA-c, is a 16-amino-acid peptide that was first discovered in 2013. It is encoded by the mitochondrial 12S rRNA gene, which is a gene that is found in the mitochondria, the energy-producing organelles of the cell.
MOTS-c was discovered by a team of researchers at the University of California, Berkeley, while they were studying the effects of interferon on gene expression in human myeloblasts. Interferon is a cytokine that is released by the body in response to infection or stress. The researchers found that interferon induced the expression of several genes in the mitochondria, including the gene for MOTS-c.
Further research showed that MOTS-c is a mitochondrial-derived peptide that is transported to the nucleus, where it regulates the expression of genes involved in metabolism and stress response. MOTS-c has also been shown to play a role in regulating the circadian rhythm, the body’s natural sleep-wake cycle.
MOTS-c is a relatively new peptide, and research on its potential benefits is still in its early stages. However, the results so far are promising. MOTS-c has been shown to improve insulin sensitivity, promote glucose uptake into muscle cells, increase fat burning, protect the mitochondria from damage, promote mitochondrial biogenesis, reduce inflammation, protect against oxidative damage, promote cellular repair, and protect against neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease in animal studies.
MOTS-c Peptide Research
MOTS-c research is still in its early stages, but the results so far are promising. Some of the key findings from MOTS-c research include:
- MOTS-c improves insulin sensitivity and glucose metabolism in animal studies.
- MOTS-c increases muscle mass and strength in animal studies.
- MOTS-c increases bone density and reduces the risk of fractures in animal studies.
- MOTS-c protects against neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease in animal studies.
- MOTS-c protects against heart disease and stroke in animal studies.
MOTS-c Peptide Clinical Trials
There are currently a few clinical trials underway to investigate the safety and efficacy of MOTS-c in humans. One clinical trial is investigating the use of MOTS-c to treat obesity. Another clinical trial is investigating the use of MOTS-c to treat type 2 diabetes.
MOTS-c Peptide Supplements
MOTS-c supplements are becoming increasingly popular among bodybuilders and athletes, who believe that they can help to improve muscle mass, strength, and performance. However, it is important to note that there is limited scientific evidence to support the use of MOTS-c supplements for these purposes.
Conclusion
MOTS-c is a promising new therapeutic target for a variety of conditions. Research is ongoing to determine the safety and efficacy of MOTS-c in humans and to develop new MOTS-c formulations.
Potential Future Directions for MOTS-c Research
Some of the potential future directions for MOTS-c research include:
- Investigating the use of MOTS-c to treat other conditions, such as cancer, cardiovascular disease, and neurological disorders.
- Developing new methods to deliver MOTS-c to the body, such as through oral administration or transdermal delivery.
- Identifying the optimal dosage and formulation of MOTS-c for different conditions.
- Evaluating the long-term safety and efficacy of MOTS-c in humans.
MOTS-c is a new and exciting area of research with the potential to lead to new and innovative treatments for a variety of conditions.
